Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference
SAN FRANCISCO, Nov. 21, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema", or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ... ET.
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, Nov. 21, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema", or "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ... ET.
Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday - Cipher Mining ( NASDAQ:CIFR ) , Aduro Clean Technologies ( NASDAQ:ADUR )
U.S. stocks were higher, with the Dow Jones gaining more than 250 points on Thursday. Shares of Nutex Health Inc ( NASDAQ:NUTX ) rose sharply during Thursday's session after the company reported better-than-expected third-quarter financial results.
Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema" or "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock - Olema Pharmaceuticals ( NASDAQ:OLMA )
Shares of Olema Pharmaceuticals, Inc. ( NASDAQ:OLMA ) soared Tuesday in reaction to Roche Holdings AG's ( OTC:RHHBY ) phase 3 results from the lidERA Breast Cancer study of giredestrant in early-stage breast cancer. "Pharma Bro" and notorious bear Martin Shkreli is shorting Olema stock.
Amer Sports Posts Upbeat Q3 Earnings, Joins Diginex, James Hardie Industries And Other Big Stocks Moving Higher On Tuesday - Alumis ( NASDAQ:ALMS ) , Ardent Health ( NYSE:ARDT )
U.S. stocks were lower, with the Dow Jones index falling more than 500 points on Tuesday. Shares of Amer Sports, Inc. ( NYSE:AS ) rose sharply during Tuesday's session after the company reported better-than-expected third-quarter financial results and raised its FY25 guidance above estimates.
Why Is Olema Pharmaceuticals Stock Soaring Today? - Olema Pharmaceuticals ( NASDAQ:OLMA ) , Roche Holding ( OTC:RHHBY )
Olema Pharmaceuticals Inc. ( NASDAQ:OLMA ) stock is trading higher on Tuesday, with a session volume of 45.12 million compared to the average volume of 1.171 million as per data from Benzinga Pro.
Dow Falls Over 300 Points; Home Depot Posts Downbeat Earnings - Creative Global Tech ( NASDAQ:CGTL ) , Can Fite Biofarma ( AMEX:CANF )
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 300 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.79% to 46,222.90 while the NASDAQ declined 0.76% to 22,531.74. The S&P 500 also fell, dropping, 0.37% to 6,647.90.
Why Gorilla Technology Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Autonomix Medical ( NASDAQ:AMIX ) , Aspire Biopharma Hldgs ( NASDAQ:ASBP )
Shares of Gorilla Technology Group Inc. ( NASDAQ:GRRR ) rose sharply in pre-market trading after the company reported financial results for the third quarter. Gorilla Technology reported third-quarter revenue of $26.5 million, up 32% on a year-over-year basis.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema" or "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema", or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025
SAN FRANCISCO, Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
San Francisco is making a comeback. So are these stocks from the City by the Bay
CNBC's Brian Sullivan sought to find the companies based in the city that were making investors the most money this year.
Top 3 Health Care Stocks You'll Regret Missing In October - Bayer ( OTC:BAYRY ) , Exelixis ( NASDAQ:EXEL )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Addex Therapeutics ( NASDAQ:ADXN ) , Alumis ( NASDAQ:ALMS )
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Monday. Shares of Olema Pharmaceuticals Inc ( NASDAQ:OLMA ) fell 18.3% to $7.64 in pre-market trading after the company announced new data from the Phase 1b/2 trial of palazestrant plus ribociclib in ...
Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket - Beyond Meat ( NASDAQ:BYND ) , Addex Therapeutics ( NASDAQ:ADXN )
Shares of Delcath Systems Inc ( NASDAQ:DCTH ) rose sharply in pre-market trading after the company announced preliminary third quarter 2025 financial results. The company's Phase 2 CHOPIN study achieved primary endpoint, with PHP plus immunotherapy extending median PFS to 12.8 months versus ...
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025 - Olema Pharmaceuticals ( NASDAQ:OLMA )
Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patients
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule ...
OLMA Stock Soars 47% in September So Far on Second PFE Deal
Olema Pharmaceuticals surges 47% in September after striking a second collaboration with Pfizer for its lead breast cancer product candidate, palazestrant.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology to Participate in Upcoming Investor Conferences - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema", or "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema", or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, July 02, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, July 02, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema" or "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, June 03, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, June 03, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema" or "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting - Olema Pharmaceuticals ( NASDAQ:OLMA )
90 mg once-daily palazestrant dose selected for Part 2 of the Phase 3 OPERA-01 monotherapy trial and for the Phase 3 OPERA-02 combination trial with ribociclib OPERA-01 trial-in-progress poster to be presented on Monday, June 2 between 9:00am-12:00pm CT / 10:00am-1:00pm ET
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 21, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals ( OLMA ) : Can the Stock Really Move This High?
The consensus price target hints at a 386.4% upside potential for Olema Pharmaceuticals (OLMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 09, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema", "Olema Oncology", Nasdaq: OLMA ) a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced ...
Olema Oncology to Participate in Upcoming Investor Conferences - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, May 09, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema", "Olema Oncology", NASDAQ:OLMA ) a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, May 02, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Wall Street Analysts Think Olema Pharmaceuticals ( OLMA ) Could Surge 433.13%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 433.1% in Olema Pharmaceuticals (OLMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals ( OLMA )
The heavy selling pressure might have exhausted for Olema Pharmaceuticals (OLMA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Compass Minerals Intl ( NYSE:CMP ) , Adaptive Biotechnologies ( NASDAQ:ADPT )
Shares of Sangamo Therapeutics, Inc. SGMO rose sharply in today's pre-market trading after the company announced a new agreement with pharmaceutical giant Eli Lilly And Co LLY, granting the company a worldwide exclusive license to leverage the company's novel proprietary neurotropic ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, April 02, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session - EyePoint Pharmaceuticals ( NASDAQ:EYPT ) , Cormedix ( NASDAQ:CRMD )
U.S. stock futures were higher this morning, with the Dow futures gaining around 150 points on Friday. Shares of Li Auto Inc. LI fell sharply in today's pre-market trading after the company reported fourth-quarter results. Li Auto posted quarterly adjusted EPADS of 52 cents, up from 30 cents in ...
Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Applied Optoelectronics ( NASDAQ:AAOI ) , Bit Origin ( NASDAQ:BTOG )
Shares of Rubrik, Inc. RBRK rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quarter guidance above estimates. Rubrik reported quarterly losses of 61 cents per share, which beat the analyst consensus ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, March 04, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference
SAN FRANCISCO, Feb. 19, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, Feb. 19, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema" or "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule ...
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Feb. 03, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Jan. 03, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 02, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, Jan. 02, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema" or "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
NVS' phase III study on experimental gene therapy candidate Intrathecal onasemnogene abeparvovec (OAV101IT) meets its primary goal.
